Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-05-15T23:39:12.311Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary: Cognitive Enhancement: Are the Claims of Critics “Good Enough”?

Published online by Cambridge University Press:  22 September 2017

Vojin Rakić
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Departments and Columns
Information
Cambridge Quarterly of Healthcare Ethics , Volume 26 , Special Issue 4: Clinical Neuroethics , October 2017 , pp. 693 - 698
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Notes

1. Greely, H, Sahakian, B, Harris, J, Kessler, RC, Gazzaniga, M, Campbell, P, Farah, MJ. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008;456(7223):702–5, at 703.CrossRefGoogle ScholarPubMed

2. Some supporters of enhancement technologies even argue that it is not only morally permissible to use enhancement technologies to make people more healthy, longer-lived and smarter, but that we are morally obliged to do so (e.g., Harris J. Enhancing Evolution: The Ethical Case for Making Better People. Princeton: Oxford University Press; 2010; or Savulescu J. Genetic interventions and the ethics of enhancement of human. In: Steinbock B, ed. The Oxford Handbook of Bioethics. Oxford: Oxford University Press; 2007:516–35.). It is beyond the scope of this commentary to discuss this issue and take a position on it.

3. Mehlman, MJ. Cognition-enhancing drugs. The Milbank Quarterly 2004;82(3):483–506, at 492.CrossRefGoogle ScholarPubMed

4. See note 3, Mehlman 2011, at 127.

5. Garasic MD, Lavazza A. Moral and social reasons to acknowledge the use of cognitive enhancers in competitive-selective contexts. BMC Medical Ethics, 2016; available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812634/# (last accessed 19 Jan 2017).

6. Ms. P. mentions piracetam. If we imagine that the authors of the vignette have the United States context in mind, this is additionally troublesome.